Syed Rizvi, MD
Endocrinology, Diabetes & Metabolism · Apex, NCNPI 1972639003
Payments from drug & device makers
Across 167 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boehringer Ingelheim$475
- Novo Nordisk$299
- IBSA Pharma Inc.$290
- AstraZeneca$165
- Amgen$137
- plus $1K from 27 others
What the payments were for
- Travel & lodging$79623%
- Food & beverage$2,56874%
- Education$893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $1,060 |
| Boehringer Ingelheim | 33 | $475 |
| Novo Nordisk | 27 | $299 |
| IBSA Pharma Inc. | 11 | $290 |
| AstraZeneca | 12 | $165 |
| Amgen | 2 | $137 |
| Sanofi-aventis U.S. LLC | 7 | $135 |
| Lilly USA, LLC | 7 | $111 |
| Radius Health, Inc. | 6 | $106 |
| AbbVie(2 entities) | 5 | $91 |
| Shire North American Group Inc | 5 | $80 |
| Amneal Pharmaceuticals LLC | 4 | $60 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| Antares Pharma, Inc. | 3 | $48 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Senseonics, Incorporated | 3 | $32 |
| Recordati_rare_diseases_inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $24 |
| Johnson & Johnson | 1 | $19 |
| Valeritas, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Bayer | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Abbott | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| BETA Bionics, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Cequr Corporation | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$638
- EVENITY$125
- Tirosint$111
- Licart$111
- FLECTOR$111
How this compares
$3,453 in reported general payments places this provider in the 60th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 314 | $421,349 |
| TrulicityDulaglutide | 203 | $272,505 |
| JardianceEmpagliflozin | 105 | $157,920 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $105,210 |
| FarxigaDapagliflozin Propanediol | 89 | $94,822 |
| MounjaroTirzepatide | 75 | $92,225 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $46,880 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $36,213 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $25,860 |
| KerendiaFinerenone | 20 | $25,819 |
| Novolog FlexpenInsulin Aspart | 88 | $23,434 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 120 | $22,532 |
| JanuviaSitagliptin Phosphate | 21 | $19,742 |
| SynthroidLevothyroxine Sodium | 201 | $19,616 |
| RybelsusSemaglutide | 11 | $18,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Levemir | $299 | $440,683336 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $111 | $367,368292 claims |
| Boehringer IngelheimJardiance | $475 | $157,920105 claims |
| AstraZenecaFarxiga | $165 | $94,82289 claims |
| MerckJanuvia, Janumet Xr | $12 | $34,37239 claims |
| BayerKerendia | $15 | $25,81920 claims |
| AbbVieSynthroid | $91 | $19,616201 claims |
| Johnson & JohnsonInvokana | $19 | $14,38813 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $60 | $6,492698 claims |
| IBSA Pharma Inc.Tirosint | $290 | $4,98115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Apex
- Kathryn LucasMorehead City$37.9M
- Mark WarrenGreenville$5M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
- Wendy LaneAsheville$1.9M
- Anthony BarberHickory$1.4M
- Klara KleinChapel Hill$1.3M
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.